Since its establishment, Kanghong Pharmaceutical Co., Ltd. has been based on the development strategy of professional innovation with product and technology innovation as the guide and clinical demand as the guide, and has conducted in-depth research, professional innovation and professional services in the core treatment field. Create a six-in-one systematic and standardized operating profit model of "focusing on the field-demand-oriented-in-depth research-patented new drugs-standardized production-professional marketing". In key technical fields, innovative technologies based on Kanghong Postdoctoral Research Center, National Enterprise Technology Center and Sichuan Provincial Key Laboratory of Bioprotein Drugs have been fully formed. The Enterprise Technology Center of Kanghong Pharmaceutical Co., Ltd. has established a number of technical platforms related to proprietary Chinese medicines, chemical medicines and biological products, including protein pharmaceutical engineering technology platform, gene therapy research and development technology platform, drug industrialization technology platform, drug screening and curative effect evaluation technology platform, pilot research technology platform of traditional Chinese medicine natural drugs, new drug preparation research technology platform, bioinformatics research technology platform, etc., to meet the needs of various new drug research and development. At present, Kanghong Pharmaceutical's product group has covered the treatment fields of central nervous system, digestive system and ophthalmology, and more than 100 patents have been applied and authorized (including more than 20 foreign patents), and 10 national projects; There are 3 major national science and technology projects of "major new drug creation", 3 national 863 plan projects, 3 national "973" plan projects 1, National Development and Reform Commission enterprise technology center innovation capacity building projects 1, scientific and technical personnel service enterprise action projects 1, National Development and Reform Commission high-tech industrialization projects 1, Sichuan.
According to "Document of Chengdu Municipal Committee 19", Chengdu Municipal Committee and Municipal Government have listed "KH series biotechnology drugs" as "strategic emerging products" in Chengdu, and given support to key projects. Among them, Kangfuxi, a new drug for the treatment of ocular fundus diseases, has entered the third clinical stage, which is expected to be the first to be listed in China at the end of 20 12, bringing good news to many patients in China.
Among Kanghong's R&D and innovation achievements, there are 1 1 varieties on the market, of which 10 are all "national medical insurance products": Songling Xuemaikang Capsule is a national basic medicine, a national patent prescription invention medicine and a famous brand product in Sichuan Province, and it is also a national traditional Chinese medicine protection product together with Yiqing Capsule and Zhenkening Capsule. Songling Xuemaikang Capsule is a basic drug for treating hypertension and preventing stroke. Yiqing capsule is a classic drug for treating "heat toxin", and it is also a recommended drug in otolaryngology-head and neck surgery and a famous brand product in Sichuan Province. Zhenkening capsule is a pure Chinese medicine preparation, which has antitussive and expectorant effects and does not contain codeine. "Danshu Capsule", a medicine used in biliary system, is a natural plant medicine, which has a unique dual cholagogic approach and can repair biliary dyskinesia. It is the exclusive product of Kanghong, and has won the gold medal of the National Spark Science and Technology Exhibition and the Chengdu Excellent New Product Award. "Gankeshuangqing Capsule" is an efficient plant monomer drug specially used for treating upper respiratory tract infection and acute bronchitis. The listed SNRI antidepressant "Bolexin" and DSS antipsychotic "Bosiqing" and digestive tract prokinetic drug "Silona" have all been included in the national torch plan. Shugan Jieyu Capsule, a Chinese patent medicine for treating mild to moderate depression, and Keluoxin Capsule for treating diabetic nephropathy are both "patented drugs invented by the state prescription". 20 10, Kanghong listed a new generation of sedative and hypnotic drug "Itonin-dextrozopiclone Tablets".
Kanghong not only constructs the core advantages of the enterprise through the research and development of patented new drugs, but also regards product quality as the life of the enterprise. It is precisely because of the constant pursuit of "perfection" in drug quality that Kanghong joined hands closely with American Sagent Holding Co in 2006 and jointly invested with * * to establish Kanghong Jinsai (Chengdu) Pharmaceutical Co., Ltd. The joint venture company was built according to the cGMP standard of the United States and will pass the FDA certification. Kanghong Jinsai (Chengdu) Pharmaceutical Co., Ltd., as the group's export preparation production base, has the world's advanced fully enclosed injection production line, which has been completely installed and is expected to be put into production in 20 12.
In order to ensure the quality of Chinese patent medicine products, Kanghong started from the source of Chinese herbal medicines. 20 1 1, Kanghong officially invested in the construction of GAP base in Fushun County, Zigong City. Relying on the construction of the national key Pinus massoniana seed base in Fushun Forest Farm, it will provide stable and uniform high-quality raw materials for Songling Xuemaikang Capsule, a national essential drug exclusively produced by the group.